30 May 2017 EMA/196621/2015 Veterinary Medicines Division

ESVAC species Expert Advisory Group Terms of reference 2016 – 2017

1. General considerations The European Medicines Agency (EMA) has been mandated by the European Commission to take the lead in coordinating the collection by Members States of harmonised national sales data of antimicrobial (AM) agents for animals, as well as estimates on consumption in the major species. Collection of sales data should ensure harmonisation with data on consumption in human medicine collected within the framework of the European Surveillance of Antimicrobial Consumption Network (ESAC-Net) funded by the European Centre for Disease Prevention and Control (ECDC). The main aim of the European Surveillance of Veterinary Antimicrobial Consumption (ESVAC) activity is to obtain harmonised and reliable data on the consumption of veterinary AM agents from all the European Union/European Economic Area (EU/EEA) countries as input for risk profiling, risk assessment and setting risk management priorities with regards to the containment of antimicrobial resistance at the EU/EEA level. The ESVAC activity is organised into three work streams: collection of overall sales data, establishing and maintaining lists of defined daily doses for animals (DDDvet) and defined course doses for animals (DCDvet) and providing guidance for collection of harmonised and standardised data on antimicrobial use by species. Separate Expert Advisory Groups have been established for these three work streams.

2. Objectives of work stream The objective of ESVAC in the area of monitoring antimicrobial use by species is to foster and facilitate the collection of harmonised and standardised data in the EU/EEA countries on the use of antimicrobials by species by providing guidance for collecting antimicrobial use data in pigs, poultry (broilers and turkeys) and cattle. These data should eventually allow for an integrated analysis with data on the use of antimicrobials in humans and on resistance in animals, humans and food.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

3. Role of ESVAC – collection of data by species The role of the ESVAC team is to: 

develop, in conjunction with the ESVAC species Expert Advisory Group, guidance and documents related to this guidance, including testing of these if considered necessary, for collection of data on use of antimicrobial agents by species at national level in the EU/EEA countries;



suggest, in conjunction with the ESVAC species Expert Advisory Group, appropriate indicators for reporting of the data;



stimulate EU/EEA countries to collect data on use of antimicrobial agents by species.

4. Terms of reference ESVAC species Expert Advisory Group The ESVAC species Expert Advisory Group will guide the ESVAC team in discussions on technical, epidemiological and other scientific aspects of surveillance of use of veterinary antimicrobials by species. It will specifically provide advice to the ESVAC team on: 

development of guidance and documents related to this guidance for data collection on antimicrobial use by species;



how to stimulate data collection in more EU/EEA countries;



development of appropriate indicators which are feasible and useful for analysing and reporting use data by species;



preparation of reports from trials;



other activities as required.

The ESVAC species Expert Advisory Group is an informal group that will be integrated into the organisation of the ESVAC project as shown in the following chart. Figure 1. ESVAC Project organization

ESVAC species Expert Advisory Group EMA/196621/2015

Page 2/3

5. Composition ESVAC species Expert Advisory Group The ESVAC species Expert Advisory Group is composed of a limited number of experts (5 to 6) from the ESVAC species National Contact Points (NCs) network or external institutions. The experts should i) have experience in collecting data on consumption of antimicrobials in pigs, poultry and/or cattle, ii) to the extent possible geographically represent the different areas of the EU, and iii) to the extent possible represent different types of species data collection systems (continuous, cross-sectional, etc.). Membership of the ESVAC species Expert Advisory Group will be by invitation from the ESVAC team. The Agency will nominate a chair of the ESVAC species Expert Advisory Group. As participation in the ESVAC species Expert Advisory Group is based on individual expertise it cannot be delegated to others. The ESVAC network of main NCs and of species NCs will be informed about the nomination. The Commission, a member of the ECDC dealing with the ESAC-Net and a representative from the European Food Safety Authority (EFSA) may be invited as observers of the ESVAC species Expert Advisory Group meetings. One or two members of the ESVAC sales Expert Advisory Group, or other experts as appropriate according to the agenda of the meetings, might be invited as observers on an ad hoc basis when considered necessary – e.g. for mutual information.

6. Meetings The ESVAC species Expert Advisory Group will mainly have virtual meetings (Adobe Connect) as required. Most communications within the group will be via email or virtual meetings. The principles for ensuring the confidentiality of data supplied to the ESVAC activity (EMA/327935/20101) apply when data is shared with the ESVAC species Expert Advisory Group to aid discussion.

7. Duration of activity The appointment of members of the ESVAC species Expert Advisory Group will be for a period of one year, which could be extended to two or three years. In order to make use of the expertise from other Member States and also to ensure the continuity in the group, at least one third of the ESVAC species Expert Advisory Group members should be replaced during the next nomination period.

8. Members (2016 – 2017) 

Fraser Broadfoot



Claire Chauvin (Chair)



Dick Heederik



Henriette Helin-Soilevaara



Miguel A. Moreno



Lucie Pokludová

1

http://www.ema.europa.eu/docs/en_GB/document_library/Other/2011/03/WC500104214.pdf

ESVAC species Expert Advisory Group EMA/196621/2015

Page 3/3

ESVAC species Expert Advisory Group - European Medicines Agency

May 30, 2017 - to obtain harmonised and reliable data on the consumption of veterinary ... These data should eventually allow for an integrated analysis with.

176KB Sizes 3 Downloads 172 Views

Recommend Documents

ESVAC species Expert Advisory Group - European Medicines Agency
May 30, 2017 - ... of the meetings, might be invited as observers on an ad hoc basis when ... Most communications within the group will be via email or virtual ...

ESVAC vision and strategy 2016-2020 - European Medicines Agency
Dec 21, 2016 - Send a question via our website www.ema.europa.eu/contact .... years. In 2015, ESVAC developed and launched a web-based reporting tool ...

Notice - European Medicines Agency
Apr 28, 2017 - 2. The United Kingdom will then become a 'third country'. 3. Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. In view of the considerable uncertainties, in parti

Report - European Medicines Agency
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.

Human Medicines Highlights Newsletter - European Medicines Agency
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. • Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. • Feraccru (ferr

Veterinary medicines highlights 2016 - European Medicines Agency
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...

Human Medicines Highlights Newsletter - European Medicines Agency
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...

Human Medicines Highlights Newsletter - European Medicines Agency
The new EudraVigilance system and the electronic reporting of individual case ... the ISO/ICH E2B(R3) format: hands-on training course - October 2017 ... granted a conditional marketing authorisation on the basis of less complete clinical data ...

Agenda - European Medicines Agency - europa.eu
4 days ago - EMA/CAT/426129/2018. Page 2/17. Table of contents. 1. Introduction. 5. 1.1. Welcome and declarations of interest of members, alternates and ...

Finasteride - European Medicines Agency - europa.eu
Apr 25, 2018 - Page 2/8. Product Name (in authorisation country). MRP/DCP. Authorisation number. National Authorisation Number. MAH of product in the.

Agenda - European Medicines Agency - europa.eu
Sep 8, 2016 - 3-year report on Pharmacovigilance activities. Helen Lee, European Commission. •. Scanning the horizon for 2016 – 2018. Peter Arlett, EMA.

Human medicines highlights newsletter - European Medicines Agency
PCWP and HCPWP joint meeting - Sept 2016 - meeting documents. • Workshop on identifying opportunities for 'big data' in medicines development and ...

Human Medicines Highlights Newsletter - European Medicines Agency
Used for the management of hypovolaemia (low blood volume) caused by acute (sudden) blood loss .... EMA's Business Continuity Plan for Brexit published.

Agenda - European Medicines Agency veterinary medicines ...
On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to enter our industry lounge, which you are welcome to utilise during your visit. The industry loung

Human Medicines Highlights Newsletter - European Medicines Agency
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a ... Withdrawal of applications for new medicines .... fifth annual regulatory conference on optimising the development of advanced therapies to.

Veterinary medicines highlights 2016 - European Medicines Agency
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...

Human Medicines Highlights Newsletter - European Medicines Agency
Implant used to help new bone develop in patients with spinal disc problems and leg fractures .... E-mail [email protected] Website www.ema.europa.eu.

Human Medicines Highlights Newsletter - European Medicines Agency
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to ...

Registration form - European Medicines Agency
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.

Agenda - European Medicines Agency - europa.eu
Jun 18, 2018 - 27. 7.8.1. List of all applications submitted/expected and the COMP coordinatorship distribution of .... 5,10-dihydrodibenzo[b,e][1,4] diazepin-11-one, EMA/OD/031/10 Glutathione-pegylated ...... Abbreviations / Acronyms.

Committee_Meeting dates_2017 - European Medicines Agency
Sep 26, 2016 - An agency of the European Union. Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555. Send a question via our website ...

Registration form - European Medicines Agency
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.

dexlansoprazole, lansoprazole - European Medicines Agency
European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 13 September 2017. EMA/727763/2017. Human Medicines Evaluation Division. List of nationally authorised medicinal products. Active substance(s): dexlansop

monthly figures - December 2016 - European Medicines Agency
Jan 10, 2017 - Applicants can request a re-examination. The first four rows present the outcome of the evaluation before a re-examination (or a.